2026-01-27 - Analysis Report
**Financial Analysis Report for Abbott Labs (ABT)**

**Company Overview**
Abbott Labs is a multinational healthcare company that develops and manufactures pharmaceuticals, medical devices, and nutritional products.

**Return Rate Comparison**

* Ticker: ABT
* Comparison: S&P 500 (VOO)
* Cumulative Return:
	+ ABT: 55.81%
	+ VOO: 127.58%
* Divergence (max: 72.30, min: -72.50, current: -72.50, relative divergence: 0.00%)

The cumulative return of ABT is significantly lower than that of the S&P 500, indicating a degree of divergence of -72.50.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 54.0% | 11.7% | 45.0% | 1.1 | 125.9B |
| 2017-2019  | 64.0% | 11.7% | 39.0% | 1.0 | 151.2B |
| 2018-2020  | 51.0% | 29.7% | 27.0% | 0.9 | 190.6B |
| 2019-2021  | 76.0% | 29.7% | 12.0% | 0.8 | 244.9B |
| 2020-2022  | 0.0% | 28.9% | -4.0% | 0.8 | 191.1B |
| 2021-2023  | -56.0% | 26.1% | -74.0% | 0.7 | 191.6B |
| 2022-2024  | -43.0% | 21.3% | -72.0% | 0.7 | 196.9B |
| 2023-2025  | 7.0% | 19.0% | -69.0% | 0.3 | 218.1B |

The Alpha and Beta values indicate varying levels of excess return and systematic risk over time.

**Recent Stock Price Fluctuations**

* Close: $108.77
* Last-market: {'price': 108.77, 'previousClose': 107.42, 'change': 1.26}
* Moving Averages:
	+ 5-day SMA: $113.33
	+ 20-day SMA: $122.20
	+ 60-day SMA: $124.78

The recent sharp rebound in price may indicate a fluctuation issue.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.70 (Medium Investment)
* RSI: 13.83
* PPO: -1.59
* Hybrid Signal: Buy
* Recent (20 days) relative divergence change: -0.50 (-)
* 7-day Rank change: 8 (+)
* 7-day Dynamic Expected Return change: 721.10 (+)
* Expected Return (%): -884.20%

The indicators suggest a Medium risk level and worsening relative divergence, with a sharp rebound in price.

**Recent News & Significant Events**

* 2026-01-26: Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance (news.google.com)
* 2026-01-22: Abbott Dives 7% On Quarterly Upset As Exact Close Looms - Investor's Business Daily (news.google.com)
* 2026-01-26: Insider Purchase: CHAIRMAN AND CEO of $ABT Buys 18,800 Shares - Quiver Quantitative (news.google.com)
* 2026-01-23: Is The Fall In Abbott Stock Justified? - Forbes (news.google.com)
* 2026-01-26: Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal - simplywall.st (news.google.com)
* 2026-01-26: Evercore ISI Says Abbottâ€™s (ABT) Core Growth Drivers Are Still Intact - Insider Monkey (news.google.com)

The recent news articles suggest various opinions on the company's performance and future growth prospects.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 136.47 / 169.00 / 115.00

The analysts' consensus is a Buy recommendation with an average target price of $136.47.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |

The earnings per share (EPS) has been generally declining, while revenue has stabilized.

**Financial Information**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |

The profit margin has been relatively stable, indicating a resilient business model.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |

The return on equity (ROE) has been volatile, indicating varying levels of profitability.

**Comprehensive Analysis**

The financial analysis report highlights the following key points:

* ABT's cumulative return is significantly lower than that of the S&P 500.
* The alpha and beta values indicate varying levels of excess return and systematic risk over time.
* The recent sharp rebound in price may indicate a fluctuation issue.
* The indicators suggest a medium risk level and worsening relative divergence, with a sharp rebound in price.
* The analysts' consensus is a Buy recommendation with an average target price of $136.47.
* The earnings per share (EPS) has been generally declining, while revenue has stabilized.
* The profit margin has been relatively stable, indicating a resilient business model.

Overall, the comprehensive analysis highlights the importance of considering multiple factors when evaluating ABT's performance and future growth prospects.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.